1,127.69
price up icon0.93%   10.43
after-market After Hours: 1131.50 3.81 +0.34%
loading
Lilly Eli Co stock is traded at $1,127.69, with a volume of 2.75M. It is up +0.93% in the last 24 hours and up +5.89% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,117.26
Open:
$1126.99
24h Volume:
2.75M
Relative Volume:
0.88
Market Cap:
$1.01T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
40.59
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+2.65%
1M Performance:
+5.89%
6M Performance:
+4.71%
1Y Performance:
+42.33%
1-Day Range:
Value
$1,114.00
$1,145.43
1-Week Range:
Value
$1,079.22
$1,145.43
52-Week Range:
Value
$623.78
$1,182.73

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
50,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2026-08-06
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LLY icon
LLY
Lilly Eli Co
1,127.69 996.31B 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
244.88 580.14B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
243.14 415.00B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
125.45 297.86B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
155.12 292.17B 54.66B 13.58B 16.05B 7.0171

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-26 Downgrade HSBC Securities Hold → Reduce
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
11:57 AM

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? - AOL.com

11:57 AM
pulisher
11:38 AM

Eli Lilly CEO announces Trump-backed Medicare program offering weight loss drugs for $50 a month - Fox Business

11:38 AM
pulisher
11:18 AM

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? - The Motley Fool

11:18 AM
pulisher
11:17 AM

Eli Lilly (LLY) Announces Medicare Coverage for Obesity Medicati - GuruFocus

11:17 AM
pulisher
11:08 AM

Eli Lilly CEO launches Medicare GLP-1 bridge program after working closely with Trump admin - Fox Business

11:08 AM
pulisher
10:45 AM

Lilly taps Abbisko for $1.9B discovery deal - BioWorld News

10:45 AM
pulisher
10:02 AM

Eli Lilly launches India's first RET-targeted therapy for solid tumours - Business Standard

10:02 AM
pulisher
09:56 AM

Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - Benzinga

09:56 AM
pulisher
09:01 AM

5 Trending US Stocks to Buy Now - Insider Monkey

09:01 AM
pulisher
08:43 AM

Eli Lilly (LLY) Expands Medicare GLP-1 Coverage for Weight Management - GuruFocus

08:43 AM
pulisher
08:04 AM

Eli Lilly launches cancer drug Tanstrive in India - The Economic Times

08:04 AM
pulisher
06:45 AM

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management - PR Newswire

06:45 AM
pulisher
06:00 AM

Eli Lilly suspends access to drug discounts for some hospitals - reporter.net

06:00 AM
pulisher
04:03 AM

Nancy Pelosi Stock Tracker Flags Eli Lilly, Nokia After Trump Praise: ‘Keep An Eye On These Two’ - Benzinga

04:03 AM
pulisher
04:00 AM

Eli Lilly’s dispensing and delivery service LillyDirect comes to UK - Chemist+Druggist

04:00 AM
pulisher
02:39 AM

Eli Lilly signs new partnership deal with China's Abbisko - medwatch.com

02:39 AM
pulisher
01:00 AM

FTAV’s further reading - Financial Times

01:00 AM
pulisher
12:21 PM

Eli Lilly and Company (LLY) – Among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors - Insider Monkey

12:21 PM
pulisher
Jun 24, 2026

Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration - Forbes

Jun 24, 2026
pulisher
Jun 24, 2026

Lilly’s GLP-1 windfall fuels M&A ‘land grab’ across 10 deals, $25B - BioWorld News

Jun 24, 2026
pulisher
Jun 24, 2026

Index Ventures entities exit Centessa (CNTA) stake as Eli Lilly acquisition closes - Stock Titan

Jun 24, 2026
pulisher
Jun 24, 2026

Centessa (CNTA) sale to Eli Lilly at $38 plus CVR detailed in Form 4 - Stock Titan

Jun 24, 2026
pulisher
Jun 24, 2026

Eli Lilly dives into hair loss treatments with investment in AI startup Absci - statnews.com

Jun 24, 2026
pulisher
Jun 24, 2026

Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI) - Seeking Alpha

Jun 24, 2026
pulisher
Jun 24, 2026

White House bats down speculation that Trump got access to Eli Lilly obesity drug - NewsNation

Jun 24, 2026
pulisher
Jun 24, 2026

Portland-area biotech receives $100M investment led by Eli Lilly - The Business Journals

Jun 24, 2026
pulisher
Jun 24, 2026

Lilly Completes Centessa Acquisition to Expand Sleep Disorder Drug Pipeline - citybiz

Jun 24, 2026
pulisher
Jun 24, 2026

At BIO, a glimpse behind Lilly and Chai’s partnership - statnews.com

Jun 24, 2026
pulisher
Jun 24, 2026

Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Benzinga

Jun 24, 2026
pulisher
Jun 24, 2026

Lilly Expands AI Drug Discovery Push With ‘App Store’ Model For Biotech Scientists - Pulse 2.0

Jun 24, 2026
pulisher
Jun 24, 2026

Eli Lilly (NYSE:LLY): What Does The Abbisko Deal Mean? - Kalkine Media

Jun 24, 2026
pulisher
Jun 24, 2026

Abbisko Therapeutics, Lilly Expand R&D Alliance - Contract Pharma

Jun 24, 2026
pulisher
Jun 24, 2026

LLY or PFE: Which Drugmaker Offers the Stronger Growth Story? - The Globe and Mail

Jun 24, 2026
pulisher
Jun 24, 2026

Eli Lilly and Abbisko Announce Drug Development Collaboration - Pharmaceutical Executive

Jun 24, 2026
pulisher
Jun 24, 2026

Is Eli Lilly and Company (LLY) Strengthening Its Pain Management Strategy With New Biotech Acquisition? - Insider Monkey

Jun 24, 2026
pulisher
Jun 24, 2026

NYSE Content Update: Abridge Partners with Eli Lilly, Nvidia to Improve Healthcare - 巴士的報

Jun 24, 2026
pulisher
Jun 24, 2026

Lilly closes Centessa deal to pursue narcolepsy and sleep-wake drugs - Stock Titan

Jun 24, 2026
pulisher
Jun 24, 2026

Abbisko Therapeutics Partners with Eli Lilly (LLY) for $1.9B R&D Collaboration - GuruFocus

Jun 24, 2026
pulisher
Jun 24, 2026

Eli Lilly reunites with Abbisko in $1.9B, multitarget R&D pact - Fierce Biotech

Jun 24, 2026
pulisher
Jun 24, 2026

White House Denies Report Linking Trump To Eli Lilly's Experimental Obesity Treatment: 'Not For The President' - Benzinga

Jun 24, 2026
pulisher
Jun 24, 2026

Eli Lilly (LLY) Invests in AI Drug Development Amid Patent Expirations - GuruFocus

Jun 24, 2026
pulisher
Jun 24, 2026

China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says - Reuters

Jun 24, 2026
pulisher
Jun 23, 2026

Abbisko Therapeutics enters potential US$1.9 billion R&D deal with Eli Lilly - The Standard (HK)

Jun 23, 2026
pulisher
Jun 23, 2026

Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly - Reuters

Jun 23, 2026
pulisher
Jun 23, 2026

Who got experimental Eli Lilly obesity drug? Not Trump, White House says - Yahoo News UK

Jun 23, 2026
pulisher
Jun 23, 2026

Abbisko Therapeutics Deepens R&D Collaboration with Lilly - PR Newswire

Jun 23, 2026
pulisher
Jun 23, 2026

Is Trump on an Experimental Weight Loss Drug? An Investigation. - New York Magazine

Jun 23, 2026
pulisher
Jun 23, 2026

Trump lauds Eli Lilly’s $3.5B venture in Lehigh Valley, Pa. workforce in Mack Trucks speech - Yahoo

Jun 23, 2026
pulisher
Jun 23, 2026

Fact check: Who did Eli Lilly give access to its obesity drug? White House says not Trump - Yahoo

Jun 23, 2026
pulisher
Jun 23, 2026

White House denies Trump is the ‘well-connected’ man who gained compassionate access to obesity drug in April - The Independent

Jun 23, 2026
pulisher
Jun 23, 2026

UBS offers autocallable notes linked to Eli Lilly (due 2029) | AMUB Prospectus Summary - Stock Titan

Jun 23, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
JNJ JNJ
$244.88
price up icon 1.61%
$243.14
price up icon 3.51%
MRK MRK
$125.45
price up icon 4.02%
NVS NVS
$155.12
price up icon 1.31%
AZN AZN
$185.68
price up icon 1.45%
Cap:     |  Volume (24h):